The US Food and Drug Administration (FDA) has approved the first nalmefene hydrochloride auto-injector (Zurnai; Purdue Pharma LP) for the treatment of known or suspected opioid overdose in people aged 12 years or older. Zurnai delivers 1.5 mg of the opioid receptor antagonist nalmefene subcutaneously or intramuscularly and is a single-dose…
